LMHRA: Mendicorma Border Unregistered Medicines Seized, L$2.2M

• The LMHRA, in collaboration with security forces, confiscated L$2.2 million in unregistered "Reality Extra D" (Diclofenac Sodium) at the Mendicorma Border.
• The seized consignment of 44 cartons originated from Sierra Leone and lacked proper regulatory approval for circulation in Liberia.
• This seizure is part of LMHRA's intensified efforts to combat unauthorized medical products and protect public health.
• LMHRA also conducted a L$400,000 confiscation of illicit medicines in Bong County in May 2026.
• The Authority urges all stakeholders to report suspicious medicines and purchase only from licensed sources to support regulatory compliance.

Pharmaceutical businesses and importers operating in Liberia must ensure rigorous compliance with LMHRA registration requirements for all medicines, especially those crossing borders.

The Liberia Medicines & Health Products Regulatory Authority (LMHRA), working in concert with joint security forces and the Lofa County Pharmacist, recently intercepted a significant consignment of unregistered medicines at the Mendicorma Border. This operation resulted in the confiscation of pharmaceutical products estimated to be worth approximately L$2.2 million. The seized goods, which originated from neighboring Sierra Leone, consisted of 44 cartons of "Reality Extra D," a pharmaceutical containing Diclofenac Sodium 50 mg.

The LMHRA Region-2 team, in close coordination with border security personnel and local county health authorities, spearheaded the seizure. Pharmacist Morrison Tambah, who manages LMHRA Region-2, underscored the Authority's unwavering commitment to safeguarding the health of the Liberian populace from potentially hazardous and unauthorized medical products. He affirmed that this confiscation serves as a clear indicator of LMHRA's proactive surveillance efforts. Pharmacist Tambah further articulated the Authority's intent to enhance its monitoring systems and collaborate closely with border security and other pertinent bodies to guarantee that only quality-assured medicines are permitted to enter and circulate within the Liberian market. This incident highlights the ongoing challenges of LMHRA Mendicorma Border unregistered medicines entering the country.

Diclofenac Sodium, a widely utilized non-steroidal anti-inflammatory medication, like all pharmaceutical products, is subject to stringent regulatory standards. These requirements are in place to ensure its quality, safety, efficacy, and appropriate use. The presence and circulation of unregistered medicines severely undermine Liberia's established pharmaceutical regulatory system, posing a direct risk to consumers who may be exposed to products of unverified quality, safety, or effectiveness. The Liberia Medicines & Health Products Regulatory Authority is the statutory body specifically tasked with regulating, inspecting, and controlling the entire lifecycle of medicines and health products within Liberia, from manufacturing to importation, distribution, and ultimate use.

The successful interdiction at the Mendicorma Border underscores the critical importance of collaborative efforts among various agencies. LMHRA management publicly acknowledged the vital contributions of the joint security forces stationed at the border and the Lofa County Pharmacist in this operation. Such inter-agency cooperation is deemed essential for bolstering border surveillance capabilities and effectively preventing the illegal entry of unauthorized medical products Liberia. These concerted actions are fundamental to Liberia pharmaceutical regulation enforcement, aiming to uphold public health standards by ensuring that all medical products meet rigorous compliance benchmarks.

This recent Reality Extra D Diclofenac Sodium seizure is not an isolated event but rather the latest in a series of robust enforcement actions undertaken by the LMHRA to combat the proliferation of adulterated, substandard, falsified, and unregistered medicines. The Authority has reiterated its dedication to intensifying surveillance, inspection, and enforcement activities, particularly focusing on major border entry points. These ongoing efforts align with LMHRA's overarching mission to ensure that all medicines and health products available within Liberia adhere to established standards of quality, safety, efficacy, and regulatory compliance, thereby actively protecting and promoting public health.

As an example of their sustained vigilance, the LMHRA Region-2 team also conducted extensive inspection and enforcement operations in Bong County in May 2026, which resulted in the confiscation of counterfeit, adulterated, and substandard medicines with an estimated market value of approximately L$400,000. This pattern of enforcement highlights a critical imperative for pharmaceutical businesses and importers operating in Liberia: they must ensure rigorous compliance with LMHRA registration requirements for all medicines, especially those crossing borders. Enforcement actions against unregistered products are clearly intensifying, making it crucial for compliance officers to review supply chain due diligence to mitigate risks of seizure and penalties associated with cross-border medicine smuggling Liberia. The LMHRA actively encourages the public, healthcare providers, pharmaceutical businesses, and other stakeholders to support these regulatory endeavors by reporting any suspected illegal or suspicious medicines and by ensuring that all medical products are procured exclusively from licensed and authorized sources.

Pharmaceutical businesses and importers operating in Liberia must ensure rigorous compliance with LMHRA registration requirements for all medicines, particularly those crossing borders, as enforcement actions against unregistered products are intensifying. Compliance officers should review supply chain due diligence to mitigate risks of seizure and penalties.

Source: Original reporting via Liberian Observer